294 related articles for article (PubMed ID: 23239187)
1. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.
Suzuki S; Kawamata J; Matsushita T; Matsumura A; Hisahara S; Takata K; Kitamura Y; Kem W; Shimohama S
J Neurosci Res; 2013 Mar; 91(3):462-71. PubMed ID: 23239187
[TBL] [Abstract][Full Text] [Related]
2. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.
Kem WR; Mahnir VM; Prokai L; Papke RL; Cao X; LeFrancois S; Wildeboer K; Prokai-Tatrai K; Porter-Papke J; Soti F
Mol Pharmacol; 2004 Jan; 65(1):56-67. PubMed ID: 14722237
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
Yanagida T; Takeuchi H; Kitamura Y; Takata K; Minamino H; Shibaike T; Tsushima J; Kishimoto K; Yasui H; Taniguchi T; Shimohama S
Neurosci Res; 2008 Dec; 62(4):254-61. PubMed ID: 18845194
[TBL] [Abstract][Full Text] [Related]
4. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).
Kem WR
Behav Brain Res; 2000 Aug; 113(1-2):169-81. PubMed ID: 10942043
[TBL] [Abstract][Full Text] [Related]
5. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
6. Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease.
Takata K; Amamiya T; Mizoguchi H; Kawanishi S; Kuroda E; Kitamura R; Ito A; Saito Y; Tawa M; Nagasawa T; Okamoto H; Sugino Y; Takegami S; Kitade T; Toda Y; Kem WR; Kitamura Y; Shimohama S; Ashihara E
Neurobiol Aging; 2018 Feb; 62():197-209. PubMed ID: 29175709
[TBL] [Abstract][Full Text] [Related]
7. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
[TBL] [Abstract][Full Text] [Related]
8. α4 nicotinic acetylcholine receptor modulated by galantamine on nigrostriatal terminals regulates dopamine receptor-mediated rotational behavior.
Inden M; Takata K; Yanagisawa D; Ashihara E; Tooyama I; Shimohama S; Kitamura Y
Neurochem Int; 2016 Mar; 94():74-81. PubMed ID: 26911419
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.
Silva-Adaya D; Pérez-De La Cruz V; Villeda-Hernández J; Carrillo-Mora P; González-Herrera IG; García E; Colín-Barenque L; Pedraza-Chaverrí J; Santamaría A
Neurotoxicol Teratol; 2011; 33(2):303-12. PubMed ID: 20933078
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
El Nebrisi E; Javed H; Ojha SK; Oz M; Shehab S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023066
[TBL] [Abstract][Full Text] [Related]
11. Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson's disease.
Liu Y; Zeng X; Hui Y; Zhu C; Wu J; Taylor DH; Ji J; Fan W; Huang Z; Hu J
Neuropharmacology; 2015 Apr; 91():87-96. PubMed ID: 25486621
[TBL] [Abstract][Full Text] [Related]
12. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice.
Ryan RE; Ross SA; Drago J; Loiacono RE
Br J Pharmacol; 2001 Apr; 132(8):1650-6. PubMed ID: 11309235
[TBL] [Abstract][Full Text] [Related]
13. The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia.
Thomsen MS; Mikkelsen JD
J Neuroimmunol; 2012 Oct; 251(1-2):65-72. PubMed ID: 22884467
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
15. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
[TBL] [Abstract][Full Text] [Related]
16. Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Park JE; Leem YH; Park JS; Kim DY; Kang JL; Kim HS
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457238
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B
Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Crotty S; Fitzgerald P; Tuohy E; Harris DM; Fisher A; Mandel A; Bolton AE; Sullivan AM; Nolan Y
Eur J Neurosci; 2008 Jan; 27(2):294-300. PubMed ID: 18190522
[TBL] [Abstract][Full Text] [Related]
19. Interaction of benzylidene-anabaseine analogues with agonist and allosteric sites on muscle nicotinic acetylcholine receptors.
Arias HR; Xing H; Macdougall K; Blanton MP; Soti F; Kem WR
Br J Pharmacol; 2009 May; 157(2):320-30. PubMed ID: 19338581
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
